Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.

Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P, Leiter LA, Charbonnel B, Mareev V, Horton ES, Haffner SM, Soska V, Holman R, Bethel MA, Schaper F, Sun JL, McMurray JJ, Califf RM, Krum H.

BMJ. 2013 Dec 9;347:f6745. doi: 10.1136/bmj.f6745. Erratum in: BMJ. 2014;348:f1339.

2.

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.

Krum H, McMurray JJ, Horton E, Gerlock T, Holzhauer B, Zuurman L, Haffner SM, Bethel MA, Holman RR, Califf RM.

Cardiovasc Ther. 2010 Apr;28(2):124-32. doi: 10.1111/j.1755-5922.2010.00146.x. Epub 2010 Feb 23.

PMID:
20184589
3.

Effect of nateglinide on the incidence of diabetes and cardiovascular events.

NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM.

N Engl J Med. 2010 Apr 22;362(16):1463-76. doi: 10.1056/NEJMoa1001122. Epub 2010 Mar 14. Erratum in: N Engl J Med. 2010 May 6;362(18):1748.

4.

Effect of valsartan on the incidence of diabetes and cardiovascular events.

NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM.

N Engl J Med. 2010 Apr 22;362(16):1477-90. doi: 10.1056/NEJMoa1001121. Epub 2010 Mar 14. Erratum in: N Engl J Med. 2010 May 6;362(18):1748.

5.

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.

Latini R, Staszewsky L, Sun JL, Bethel MA, Disertori M, Haffner SM, Holman RR, Chang F, Giles TD, Maggioni AP, Rutten GE, Standl E, Thomas L, Tognoni G, Califf RM, McMurray JJ.

Am Heart J. 2013 Nov;166(5):935-40.e1. doi: 10.1016/j.ahj.2013.08.012. Epub 2013 Oct 7.

PMID:
24176451
6.
8.

The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.

Kuti EL, Baker WL, White CM.

Curr Med Res Opin. 2007 Jun;23(6):1239-44. Epub 2007 Apr 23.

PMID:
17559720
9.

Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.

Chatterjee R, Thomas L, Svetkey L, Brancati FL, Califf RM, Edelman D.

Am J Hypertens. 2013 Jun;26(6):723-6. doi: 10.1093/ajh/hpt016. Epub 2013 Feb 15.

10.

Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.

Wong YW, Thomas L, Sun JL, McMurray JJ, Krum H, Hernandez AF, Rutten GE, Leiter LA, Standl E, Haffner SM, Mazzone T, Martinez FA, Tognoni G, Giles T, Califf RM.

Circ Heart Fail. 2013 Mar;6(2):203-10. doi: 10.1161/CIRCHEARTFAILURE.112.000086. Epub 2013 Feb 6.

11.

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.

Preiss D, Giles TD, Thomas LE, Sun JL, Haffner SM, Holman RR, Standl E, Mazzone T, Rutten GE, Tognoni G, Chiang FT, McMurray JJ, Califf RM.

Stroke. 2013 Sep;44(9):2590-3. doi: 10.1161/STROKEAHA.113.001177. Epub 2013 Jul 30.

12.

Association between cardiovascular outcomes and antihypertensive drug treatment in older women.

Wassertheil-Smoller S, Psaty B, Greenland P, Oberman A, Kotchen T, Mouton C, Black H, Aragaki A, Trevisan M.

JAMA. 2004 Dec 15;292(23):2849-59. Erratum in: JAMA. 2005 Apr 6;293(13):1594.

PMID:
15598916
13.

Choice of antihypertensive treatment in subjects with pre-diabetes. Is there a dream after the navigator.

Eleftheriadou I, Tsioufis C, Tsiachris D, Tentolouris N, Stefanadis C.

Curr Vasc Pharmacol. 2011 Nov;9(6):715-22. Review.

PMID:
21470107
15.

Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.

Katz M, Califf RM, Sun JL, McMurray JJ, Thomas L, Lopes RD.

Am J Med. 2015 Mar;128(3):297-302. doi: 10.1016/j.amjmed.2014.08.022. Epub 2014 Nov 20.

PMID:
25447626
16.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group.

Lancet. 2004 Jun 19;363(9426):2022-31.

PMID:
15207952
17.

Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial.

van der Zijl NJ, Moors CC, Goossens GH, Hermans MM, Blaak EE, Diamant M.

Diabetes Care. 2011 Apr;34(4):845-51. doi: 10.2337/dc10-2224. Epub 2011 Feb 17.

18.

Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives.

Sowers JR, Raij L, Jialal I, Egan BM, Ofili EO, Samuel R, Zappe DH, Purkayastha D, Deedwania PC.

J Hypertens. 2010 Aug;28(8):1761-9. doi: 10.1097/HJH.0b013e32833af380.

19.

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL.

N Engl J Med. 2000 Mar 30;342(13):905-12.

20.

Influence of diuretics, calcium antagonists, and alpha-blockers on insulin sensitivity and glucose tolerance in hypertensive patients.

Ramsay LE, Yeo WW, Jackson PR.

J Cardiovasc Pharmacol. 1992;20 Suppl 11:S49-53; discussion S53-4. Review.

PMID:
1284144

Supplemental Content

Support Center